Comprehensive analysis of genomic alterations of Chinese hilar cholangiocarcinoma patients
Background Cholangiocarcinoma (CCA) is a rare malignant tumor of the biliary system. The heterogeneity of CCA leads to the lack of effective targeted treatment for CCA subtypes. The molecular characteristic of hilar CCA (hCCA) is still unclear. Methods A total of 63 hCCA patients were enrolled from...
Gespeichert in:
Veröffentlicht in: | International journal of clinical oncology 2021-04, Vol.26 (4), p.717-727 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
Cholangiocarcinoma (CCA) is a rare malignant tumor of the biliary system. The heterogeneity of CCA leads to the lack of effective targeted treatment for CCA subtypes. The molecular characteristic of hilar CCA (hCCA) is still unclear.
Methods
A total of 63 hCCA patients were enrolled from Shanghai Eastern Hepatobiliary Surgery Hospital. Formalin-fixed, paraffin-embedded tumor tissues, and matched blood were collected and deep sequencing targeting 450 cancer genes were performed. Tumor mutation burden (TMB) was measured by an algorithm developed in-house. Correlation analysis was performed by Fisher’s exact test.
Results
The most commonly mutated genes were
TP53
(51.7%),
NF1
and
KRAS
(20%, for both),
SMAD4
(16.7%),
FAT3
and
FRS2
(13.3%, for both),
NF1
(11.7%), and
KMT2C
,
MDM2
, and ATM (10%, for each) in hCCA.
ARID1A
,
GATA6
, and
PREX2
mutations commonly occurred in female and
KMT2C
mutations mainly occurred in patients under 60 years old. Statistical analysis showed the association between
ARID1A
mutation and tumor stage (
P
= 0.041) and between
NF1
mutation and high TMB (
P
= 0.0095). Furthermore,
ARID1B
mutation was identified to associate with the poor prognosis of Chinese hCCA patients (
P
= 0.004).
Conclusion
The mutational characterization of hCCA is different from both extrahepatic CCA and intrahepatic CCA.
ARID1B
is a potential biomarker for prognosis prediction of Chinese hCCA patients. |
---|---|
ISSN: | 1341-9625 1437-7772 |
DOI: | 10.1007/s10147-020-01846-z |